Perry A Karsen
CIK 1260573 · see remarks · last filed 2023-07-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CELGZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
86 MORRIS AVENUE
SUMMIT, NJ 07901
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (GRPH) Delisted | Director | 23,433 | $22.26 | $521.6K | $0 | 3 | 2023-07-21 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 0 | $1.88 | $0 | $80.0K | 8 | 2023-05-04 |
| NTLA | Director | 26,336 | $11.32 | $298.1K | -$4.75M | 7 | 2020-12-18 |
| VYGR | Director | — | $1.83 | — | $0 | 4 | 2019-06-17 |
| CELGENE CORP /DE/ (CELGZ) Delisted | see remarks | 68,071 | — | — | -$32.62M | 30 | 2015-12-18 |
| NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Director | 1,876 | $0.00 | $0 | $0 | 5 | 2015-07-21 |
| AGIO | Director | — | $36.35 | — | $0 | 1 | 2015-06-25 |
Recent Filings · Page 5 of 7
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-02-04 | CELGENE CORP /DE/ (CELGZ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-01-02 | CELGENE CORP /DE/ (CELGZ) Delisted | Mixed | +4,061 | -$1.49M | EDGAR |
| 2014-12-23 | CELGENE CORP /DE/ (CELGZ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-11-14 | CELGENE CORP /DE/ (CELGZ) Delisted | Mixed | −7,346 | -$3.17M | EDGAR |
| 2014-11-12 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +10,252 | $13.5K | EDGAR |
| 2014-10-29 | CELGENE CORP /DE/ (CELGZ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-08-05 | CELGENE CORP /DE/ (CELGZ) Delisted | Mixed | +7,346 | -$2.12M | EDGAR |
| 2014-07-29 | CELGENE CORP /DE/ (CELGZ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-05 | CELGENE CORP /DE/ (CELGZ) Delisted | Sell (S) | −2,408 | -$383.0K | EDGAR |
| 2014-02-19 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.